S&P 500 Healthcare Sector SEC Filings — August 11, 2026

CFO Monson Jonathan made a $500K open-market purchase of 9,908 shares at $50.46, a strong vote of confidence from a top executive with no pre-planned sale program disclosed

SVP Zakrowski sold $2.37M (2,000 shares) at $1,185.01 under a 10b5-1 plan, reducing holdings by ~57% post-sale, a notable reduction in insider exposure despite being pre-planned

Director Ladd sold 472 shares total (~$180K) in two transactions at $379 and $393.10, reducing holdings by ~72% post-sale, signaling potential lack of confidence at the board level

CVP Lippis exercised options at $72.68 and immediately sold at $92.03 for a quick ~27% gain, a routine but profit-taking move that shows no long-term accumulation [NEUTRAL/BEARISH]

EVP Cain exercised 6,002 RSUs and had 2,908 shares withheld for taxes (~$387K), a standard tax-covering transaction with no net insider buying or selling signal

Director Damelio gifted 6,650 shares, reducing holdings by ~31%, which is often a neutral estate-planning move but can signal a desire to reduce exposure without a market sale

The CFO's purchase is the only open-market buy in the entire digest, standing out as a contrarian signal of confidence in a sector where other insiders are selling or gifting shares

Despite the insider sale, the stock trades at a premium valuation, and the sale is pre-planned, but the magnitude ($2.37M) is the largest dollar transaction in the digest, warranting attention

Director Ladd sold 72% of her holdings in two transactions, the highest proportional reduction among all insiders in this digest, suggesting potential board-level concern about valuation or outlook

SVP Zakrowski now holds only 1,525 shares post-sale, a minimal stake for a senior finance executive, reducing alignment with shareholders

CVP Lippis exercised and immediately sold, a pattern that may indicate a lack of conviction in holding shares long-term, especially in a TAVR-focused role

Director Damelio gifted 31% of his holdings, which, while not a market sale, reduces insider skin-in-the-game and could precede further reductions

Despite the stock being down ~15% from 52-week highs, there is no insider buying in this filing, only tax-related sales, indicating a lack of opportunistic buying

4 out of 6 filings involve insider selling or gifting, with only 1 clear buy, suggesting a net bearish insider sentiment across the healthcare sample today

The stock trades at ~$1,185, and the insider sale, even if pre-planned, may signal that the executive believes the stock is fairly valued or overvalued at current levels

Director Ladd holds only 179 shares post-sale, a negligible amount for a board member, raising governance questions about alignment

The CFO's $500K open-market purchase is a rare and strong bullish signal; investors may view this as a catalyst to accumulate shares, especially if the stock is trading near support levels

The SVP's sale is pre-planned and may not reflect current views; the stock's strong fundamentals (Zepbound, Mounjaro) could present a buying opportunity if the sale creates a temporary dip

The EVP's exercise of 6,002 RSUs suggests the company is performing well enough to trigger equity vesting; the tax withholding sale is routine and not a negative signal

The CVP exercised options at $72.68, well below the current price of $92.03, indicating the stock is trading above key insider cost basis, which can be a floor for the stock

The director gift is likely for estate planning and does not reflect a bearish view; the stock remains a defensive healthcare play with stable animal health demand

The director's sale of 72% of holdings may create a short-term overhang, but the company's robotic surgery leadership and long-term growth trajectory could offer a buying opportunity on weakness

In a digest dominated by selling, the CFO's buy is a contrarian indicator that could signal the stock is undervalued relative to peers; investors should review the company's upcoming earnings for confirmation

The lack of uniform insider behavior suggests stock-specific opportunities; Boston Scientific's buy and Eli Lilly's sell create a potential pair trade for active investors

4 of 6 filings involve insider selling or gifting, with only 1 open-market buy, indicating a net bearish insider sentiment among healthcare executives on this date

2 of the 3 sales (Eli Lilly, Edwards Lifesciences) were executed under Rule 10b5-1 plans, making it difficult to assess current management conviction; investors should focus on open-market transactions for clearer signals

Gilead Sciences' tax withholding sale is a routine event following RSU vesting, highlighting that not all insider sales are negative; investors should distinguish between tax-driven and discretionary sales

Eli Lilly and Intuitive Surgical, both trading at premium valuations, saw insider selling, while Boston Scientific, potentially at a lower valuation, saw buying—suggesting insiders are price-sensitive

Both Intuitive Surgical (director sold 72%) and Zoetis (director gifted 31%) saw board-level reductions, which can be more significant than executive trades as directors have broader oversight

Watch for additional insider buying or a pattern of open-market purchases; the CFO's buy could be a precursor to positive news or earnings beat

Monitor for any insider buying following the SVP's sale; if other executives sell, it could confirm bearish sentiment; next earnings call expected in October 2026

Director Ladd's near-total exit warrants monitoring for further board-level sales; the company's next quarterly results will be key to assess if the sale was valuation-driven

Watch for additional option exercises and sales by TAVR leadership; the TAVR market is competitive, and insider selling could signal market share concerns

Monitor for any open-market insider buying; the lack of buying despite a recent pullback could indicate management sees further downside

The director gift could precede a formal sale; watch for Form 4 filings showing market sales in the coming weeks

Track the ratio of insider buys to sells across the S&P 500 Healthcare sector over the next month; a sustained selling bias could signal a sector top

The CFO's purchase may be timed ahead of the next earnings release; investors should mark their calendars for the upcoming earnings call (date TBD)